Rhizen Pharmaceuticals S.A. announces a scientific presentation on its novel, inhaled, dual PI3K δ/γ inhibitor for the treatment of lung diseases at the American Thoracic Society International Conference in Philadelphia (May 14, 2013)

Rhizen Pharmaceuticals and TG Therapeutics Sign Joint Venture Collaboration Agreement for Worldwide Development and Commercialization of Novel Selective PI3K δ Kinase Inhibitors (August 16, 2012)

BIO EUROPE 2013, March 11-13, Barcelona, Spain

BIO 2013, April 22-25, Chicago, II

American Thoracic Society (ATS) International Conference 2013, May 17- 23 Philadelphia, PA

18th Congress of the European Hematology Association (EHA) 2013, June 13-16 Stockholm, Sweden

Preclinical efficacy of RP6503, a novel, dual PI3K δ/ γ inhibitor in airway disorders, ATS 2013, May 17- 23 Philadelphia, PA

Therapeutics potential of dual PI3K δ/ γ inhibition in T-cell lymphoma, EHA 2013, June 13-16 Stockholm, Sweden